rare disease Archives • NCK Pharma

Evox partnership with Takeda Pharmaceutical for rare disease

Posted on29 Mar 2020

Tagsorphan drug, orphan drug design, rare disease, Takeda

Comments0

Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited. The...

Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals

Posted on07 Feb 2019

TagsAegerion, HoFH, Juxtapid, Novelion Therapeutics, orphan drug, orphan drug designation, rare disease

Comments0

Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights...

EUSA Pharma acquires global rights to Sylvant from Janssen Sciences for US$ 15 mn

Posted on19 Jul 2018

Tagsrare disease, rare diseases, Sylvant

Comments0

EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare disease, has entered into a definitive agreement with Janssen Sciences Ireland...

Pfizer’s strategic initiative to expand rare disease research

Posted on11 Dec 2014

Tagsorphan drug, Pfizer rare disease, Pfizer's strategic initiative to expand rare disease research, rare disease

Comments0

Pfizer Inc. announced two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene...